Genentech, Immunocore sign cancer drug deal worth more than $320M

Genentech and Immunocore agreed to use the latter's ImmTAC T-cell receptor technology to discover and develop new cancer targets. The collaboration will center on ImmTACs, which are bispecific biologic drugs designed to recognize intracellular changes during cancer or viral infection. Immunocore could get $10 million to $20 million in initiation fees and more than $300 million in milestone payments per target program plus sales royalties.

View Full Article in:

PharmaTimes (U.K.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA